
News|Articles|July 1, 2002
NEW WARNING: Simvastatin: Myopathy risk
New labeling for the cholesterol-loweringagent simvastatin (Zocor, Merck) highlights the risks of myopathyand rhabdomyolysis with or without acute renal failure as side effectsof the drug alone or in combination.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The Rise of AI in Healthcare Shows Both Progress and Roadblocks
2
Researchers Urge Payers to Encourage, not Inhibit, Biosimilar Competition
3
Challenges & Solutions behind post-acute care models with OneHome's Noel Gilliam
4
Izervay Continued to Show Benefit in Geographic Atrophy in Open-Label Study
5



















































